Compare DKI & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | BFRG |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.7M |
| IPO Year | 2025 | 2022 |
| Metric | DKI | BFRG |
|---|---|---|
| Price | $3.96 | $0.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 85.4K | ★ 124.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,670.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.49 |
| 52 Week Low | $0.28 | $0.43 |
| 52 Week High | $11.80 | $2.04 |
| Indicator | DKI | BFRG |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 46.82 |
| Support Level | $3.50 | $0.51 |
| Resistance Level | $5.20 | $0.69 |
| Average True Range (ATR) | 0.39 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 19.78 | 41.15 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.